Fibrogen stretches the bounds of credibility
Admission of a major data error in previous roxadustat presentations leaves the novel anaemia pill’s future in doubt.
Go or no go? A delayed decision on Evrenzo
March will see big US decisions for Evrenzo and ide-cel, while tanezumab goes in front of an advisory committee.
Asco-GU – confirmatory Padcev trial throws a curveball
Subgroup analysis of a confirmatory US study in bladder cancer suggests no benefit in female patients.
Biotech flotations offer venture funds an accelerating exit
Start-ups floated faster than usual in 2020, a new analysis finds. For a deeper look at biopharma deal trends, our free report is available to download today.
Aducanumab tops 2021’s biggest potential launches
Blockbuster sales are predicted for several projects nearing approval, from Biogen, Argenx, Fibrogen and others.
